Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer — Stella

Home/Recurrent Endometrial Carcinoma/

View on ClinicalTrials.gov

Recruiting

Back to Recurrent Endometrial Carcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

Key details

Phase

Safety & dosing

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

Eli Lilly and Company

Enrollment target

~32 participants

Started

October 2020

Primary completion

July 2026

Sex

Female only

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.